William E Brady
Overview
Explore the profile of William E Brady including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Singh M, Darcy K, Brady W, Clubwala R, Weber Z, Rittenbach J, et al.
Gynecol Oncol
. 2011 Aug;
123(2):320-8.
PMID: 21813170
Objective: We evaluated the clinical relevance of catenins, cadherins and cell cycle regulators in stage IV or recurrent endometrial carcinoma in a multi-center phase II trial (GOG protocol #119). Methods:...
32.
Coleman R, Brady W, McMeekin D, Rose P, Soper J, Lentz S, et al.
Gynecol Oncol
. 2011 Apr;
122(1):111-5.
PMID: 21497382
Background: Nab-paclitaxel is a novel Cremophor®-free nanoparticle of albumin-stabilized paclitaxel, which has favorable efficacy and toxicity characteristics relative to other solvent-based taxanes, such as paclitaxel and docetaxel. Methods: Eligible patients...
33.
Rocereto T, Brady W, Shahin M, Hoffman J, Small L, Rotmensch J, et al.
Gynecol Oncol
. 2009 Nov;
116(3):332-4.
PMID: 19922989
Objective: To evaluate the effectiveness and toxicity of mifepristone in patients with ovarian, peritoneal and fallopian tube cancers. Methods: Patients with confirmed epithelial ovarian, peritoneal and fallopian tube cancers which...
34.
Darcy K, Brady W, Blancato J, Dickson R, Hoskins W, McGuire W, et al.
Gynecol Oncol
. 2009 Jun;
114(3):472-9.
PMID: 19524285
Objective: The Gynecologic Oncology Group (GOG) examined the prognostic relevance of c-MYC amplification and polysomy 8 in epithelial ovarian cancer (EOC). Methods: Women with suboptimally-resected, advanced stage EOC who participated...
35.
Fowler J, Brady W, Grigsby P, Cohn D, Mannel R, Rader J
Gynecol Oncol
. 2009 Jan;
112(3):553-7.
PMID: 19135232
Objectives: The optimal treatment regimen for advanced stage endometrial carcinoma (EC) is yet to be established. The objective of this study was to evaluate the feasibility and toxicity of delivering...
36.
Darcy K, Brady W, McBroom J, Bell J, Young R, McGuire W, et al.
Gynecol Oncol
. 2008 Oct;
111(3):487-95.
PMID: 18834621
Objective: The Gynecologic Oncology Group (GOG) performed a detailed analysis of p53 overexpression in previously-untreated women with invasive early or advanced stage epithelial ovarian cancer (EOC). Methods: Women were eligible...
37.
Guru K, Kuvshinoff B, Pavlov-Shapiro S, Bienko M, Aftab M, Brady W, et al.
J Am Coll Surg
. 2006 Dec;
204(1):96-101.
PMID: 17189118
Background: This study objectively surveyed and compared the ability of participants to perform laparoscopic and robotic tasks, and attempted to determine the key advantages of each modality. Study Design: A...
38.
Denke M, Pearson T, McBride P, Gazzara R, Brady W, Tershakovec A
Diab Vasc Dis Res
. 2006 Oct;
3(2):93-102.
PMID: 17058629
This analysis of the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial examined the effectiveness and safety of ezetimibe 10 mg added to ongoing statin therapy in patients with diabetes,...
39.
Catapano A, Davidson M, Ballantyne C, Brady W, Gazzara R, Tomassini J, et al.
Curr Med Res Opin
. 2006 Oct;
22(10):2041-53.
PMID: 17022864
Objective: To assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses. Research Design And Methods:...
40.
Pearson T, Denke M, McBride P, Battisti W, Gazzara R, Brady W, et al.
Mayo Clin Proc
. 2006 Sep;
81(9):1177-85.
PMID: 16970214
Objective: To examine whether the improvements in lipid profiles and low-density lipoprotein cholesterol (LDL-C) goal attainment found in the Ezetimibe Add-On to Statin for Effectiveness trial occurred equally in the...